QIAGEN enters into collaboration agreement with Eli Lilly, terms not disclosed QIAGEN (QGEN) announced it has entered into a master collaboration agreement with Eli Lilly (LLY) for the development and commercialization of companion diagnostics for pairing with Lilly investigational and approved medicines across all therapeutic areas. The agreement builds on QIAGEN and Lilly's past work together. Companion diagnostics unlock a patient's molecular information in order to guide treatment decisions for specific cancers or other diseases. Financial terms of the agreement are not being disclosed. The agreement provides a framework for Lilly and QIAGEN to collaborate on future projects - across all of Lilly's therapeutic areas - aimed at bringing to market Lilly medicines paired with QIAGEN diagnostics. It also further underscores QIAGEN's leading position in partnering with global pharmaceutical companies to deliver the benefits of personalized medicine to patients and healthcare providers.